Quantedge Capital Pte Ltd Has $264,000 Stake in Amphastar Pharmaceuticals, Inc. $AMPH

Quantedge Capital Pte Ltd reduced its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 85.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,500 shares of the company’s stock after selling 78,200 shares during the quarter. Quantedge Capital Pte Ltd’s holdings in Amphastar Pharmaceuticals were worth $264,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quarry LP bought a new position in Amphastar Pharmaceuticals during the 3rd quarter worth about $32,000. Farther Finance Advisors LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 46.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after purchasing an additional 437 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 37.8% in the fourth quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock valued at $45,000 after purchasing an additional 462 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Amphastar Pharmaceuticals by 24.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock worth $60,000 after buying an additional 435 shares during the period. Finally, TD Private Client Wealth LLC boosted its position in shares of Amphastar Pharmaceuticals by 410.1% during the fourth quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock worth $65,000 after buying an additional 1,944 shares during the period. 65.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AMPH. Barclays decreased their price objective on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating for the company in a report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Zacks Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, June 22nd. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Five equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of “Reduce” and an average price target of $22.00.

Amphastar Pharmaceuticals Trading Down 0.2%

Amphastar Pharmaceuticals stock opened at $19.59 on Wednesday. The company has a market cap of $863.72 million, a price-to-earnings ratio of 11.80, a P/E/G ratio of 3.86 and a beta of 0.89. The firm has a 50-day moving average of $19.24 and a 200-day moving average of $22.04. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82. Amphastar Pharmaceuticals, Inc. has a one year low of $16.65 and a one year high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Thursday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The company had revenue of $171.17 million during the quarter, compared to analyst estimates of $173.46 million. On average, equities analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.41 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.